Strong knees and hips give leg-up to top-line for ortho companies
This article was originally published in Clinica
Abbott Labs' medical products division grew 14% in the first quarter of 2008, driven by sales of its diagnostic products, which increased 17% to $832m. Point-of-care and molecular diagnostics performed particularly strongly, growing 22% and 21%, respectively. Vascular sales, up 8% at $452m, were held back by a decline in the percutaneous coronary intervention market, resulting in lower third-party catheter sales. On the coronary stent side, sales increase 18% to $189m. Abbott said it still expects its Xience V drug-eluting stent (DES), already available internationally, to receive FDA approval in the second quarter of 2008.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.